Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00057395 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.

NCT ID: NCT00056459 Completed - Clinical trials for Colorectal Neoplasms

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Start date: February 2003
Phase: Phase 3
Study type: Interventional

To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment

NCT ID: NCT00056446 Completed - Clinical trials for Colorectal Neoplasms

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.

NCT ID: NCT00055809 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Start date: January 2003
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is to see if combining bevacizumab with PEG-interferon alfa-2b works in treating patients who have metastatic or unresectable carcinoid tumors. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. PEG-interferon alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. Combining bevacizumab with PEG-interferon alfa-2b may kill more cancer cells

NCT ID: NCT00055471 Completed - Prostatic Neoplasms Clinical Trials

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

Start date: June 2003
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

NCT ID: NCT00055263 Completed - Neoplasms Clinical Trials

A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies

Start date: March 2002
Phase: Phase 1
Study type: Interventional

The purposes of this study are to: - Test the safety of DN-101 in patients with advanced malignancies - Understand how fast the body absorbs, processes, and eliminates DN-101 - Determine the highest dose of DN-101 that is well tolerated by cancer patients - Learn how fast the body absorbs, processes, and eliminates DN-101 compared to the approved product

NCT ID: NCT00054912 Completed - Clinical trials for Colorectal Neoplasms

An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer

Start date: February 2003
Phase: Phase 1
Study type: Interventional

EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.

NCT ID: NCT00054873 Completed - Stomach Neoplasms Clinical Trials

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Start date: November 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.

NCT ID: NCT00054795 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Start date: n/a
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.

NCT ID: NCT00054041 Completed - Cervical Cancer Clinical Trials

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Start date: June 2004
Phase: Phase 2
Study type: Interventional

Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer. Randomized phase II trial to study the effectiveness of vaccine therapy in preventing cervical cancer in patients who have cervical intraepithelial neoplasia